Phase II Study to Evaluate the Efficacy of Upfront Obinutuzumab in Mantle Cell Lymphoma Patients Treated by DHAP Followed by Autologous Transplantation Plus Obinutuzumab Maintenance Then MRD Driven Maintenance

Trial Profile

Phase II Study to Evaluate the Efficacy of Upfront Obinutuzumab in Mantle Cell Lymphoma Patients Treated by DHAP Followed by Autologous Transplantation Plus Obinutuzumab Maintenance Then MRD Driven Maintenance

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2016

At a glance

  • Drugs Carmustine (Primary) ; Cisplatin (Primary) ; Cytarabine (Primary) ; Dexamethasone (Primary) ; Etoposide (Primary) ; Melphalan (Primary) ; Obinutuzumab (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms LyMa101
  • Most Recent Events

    • 26 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top